Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: VRL010
MIFTS: 60

Viral Hepatitis

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Viral Hepatitis

About this section

MalaCards integrated aliases for Viral Hepatitis:

Name: Viral Hepatitis 12 56 15 74 3
Hepatitis, Viral, Animal 45 74
Animal Viral Hepatitis 12 17
Viral Hepatitis with Hepatic Coma 12
Human Viral Hepatitis 12

Classifications:

MalaCards categories:
Global: Infectious diseases Genetic diseases Rare diseases Cancer diseases
Anatomical: Endocrine diseases Gastrointestinal diseases Liver diseases Immune diseases Skin diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:1884
MeSH 45 D006524
Sources

Summaries for Viral Hepatitis

About this section
Disease Ontology : 12 A hepatitis that involves viral infection causing inflammation of the liver.

MalaCards based summary : Viral Hepatitis, also known as hepatitis, viral, animal, is related to non-a-e hepatitis and hepatitis a. An important gene associated with Viral Hepatitis is GPT (Glutamic--Pyruvic Transaminase), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Human cytomegalovirus infection. The drugs Peginterferon alfa-2b and Peginterferon alfa-2a have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and t cells, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

CDC : 3 Surveillance summaries, guidelines and forms, disease burden

Wikipedia : 77 Viral hepatitis is liver inflammation due to a viral infection. It may present in acute form as a recent... more...

Sources

Related Diseases for Viral Hepatitis

About this section

Diseases in the Hepatitis family:

Hepatitis C Virus Autoimmune Hepatitis
Hepatitis B Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis D Hepatitis E

Diseases related to Viral Hepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 276)
# Related Disease Score Top Affiliating Genes
1 non-a-e hepatitis 33.0 ALB F2
2 hepatitis a 32.5 AFP ALB F2 GPT SEPSECS SERPINA1
3 epstein-barr virus hepatitis 32.2 ALB F2
4 hepatitis c 32.0 GGT1 GPT IFNA1 IFNA2 KRT18 TNF
5 hepatitis d 31.9 F2 GPT IFNA2
6 hepatitis e 31.1 ALB F2 GPT TNF
7 acute liver failure 30.9 ALB F2 GPT SLC17A5
8 infantile liver failure syndrome 1 30.9 ALB F2 GPT SLC17A5
9 hepatic coma 30.8 ALB F2 GPT
10 fatty liver disease 30.6 FAS GGT1 SLC17A5 TNF
11 typhoid fever 30.5 ALB F2 TNF
12 hepatitis b 30.5 AFP ALB F2 FGL2 GGT1 GPT
13 schistosomiasis 30.5 ALB F2 TNF
14 hepatitis 30.3 AFP F2 FASLG GGT1 GPT IFNA1
15 hepatocellular carcinoma 30.3 AFP ALB F2 FASLG GGT1 HFE
16 obstructive jaundice 30.2 ALB F2 GGT1 GPT SLC17A5 TNF
17 autoimmune hepatitis 30.2 F2 FAS GGT1 GPT SEPSECS
18 alcohol abuse 30.2 ABCB7 GGT1 GPT SLC17A5
19 aplastic anemia 30.1 ALB FAS FASLG HFE TNF
20 alcoholic liver cirrhosis 30.0 AFP ALB F2 SLC17A5
21 protein-energy malnutrition 30.0 ALB GPT TNF
22 opisthorchiasis 30.0 AFP GPT TNF
23 gastroenteritis 30.0 ALB IFNA1 TNF
24 hepatic encephalopathy 29.9 ALB F2 GPT SLC17A5 TNF
25 acquired immunodeficiency syndrome 29.9 ALB IFNA1 IFNA2 TNF
26 fatty liver disease, nonalcoholic 1 29.9 GPT KRT18 SLC17A5
27 portal hypertension 29.8 ALB F2 GPT TNF
28 alpha-1-antitrypsin deficiency 29.8 ALB HFE SERPINA1
29 meningitis 29.8 ALB TLR2 TNF
30 diabetes mellitus, noninsulin-dependent 29.8 ALB GGT1 GPT SLC17A5 TNF
31 graft-versus-host disease 29.8 FAS FASLG TNF
32 vasculitis 29.7 IFNA2 SERPINA1 TNF
33 severe acute respiratory syndrome 29.7 IFNA1 MX1 TNF
34 scrub typhus 29.7 GPT SLC17A5 TLR2 TNF
35 biliary atresia 29.7 ALB GPT MX1
36 cholecystitis 29.7 ALB F2 GPT KRT18
37 sickle cell anemia 29.6 F2 G6PD TNF
38 bilirubin metabolic disorder 29.5 ALB F2 G6PD GGT1 GPT SLC17A5
39 nonalcoholic steatohepatitis 29.2 F2 GPT HFE KRT18 SLC17A5 TNF
40 alcoholic hepatitis 29.2 ALB F2 GPT KRT18 SLC17A5 TNF
41 gastrointestinal system disease 29.2 AFP ALB F2 GGT1 IFNA1 SERPINA1
42 liver cirrhosis 29.0 AFP ALB F2 GGT1 GPT HFE
43 malaria 28.8 ALB FASLG G6PD TLR2 TNF
44 liver disease 28.3 ABCB7 AFP ALB F2 FAS GGT1
45 fulminant viral hepatitis 12.4
46 porphyria cutanea tarda 11.4
47 paraquat poisoning 10.5 GPT SLC17A5
48 lymphomatoid granulomatosis 10.5 IFNA1 IFNA2
49 australia antigen 10.5
50 antipyrine metabolism 10.5 ALB F2

Graphical network of the top 20 diseases related to Viral Hepatitis:



Diseases related to Viral Hepatitis
Sources

Symptoms & Phenotypes for Viral Hepatitis

About this section

GenomeRNAi Phenotypes related to Viral Hepatitis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 AFP ALB FAS FASLG FGL2 GGT1

MGI Mouse Phenotypes related to Viral Hepatitis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 ABCB7 AFP ALB F2 FAS FASLG
2 digestive/alimentary MP:0005381 9.8 ALB F2 FAS FASLG HFE TLR2
3 liver/biliary system MP:0005370 9.61 ABCB7 AFP ALB FAS FASLG HFE
4 mortality/aging MP:0010768 9.47 ABCB7 AFP ALB F2 FAS FASLG
Sources

Drugs & Therapeutics for Viral Hepatitis

About this section

Drugs for Viral Hepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 294)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2b Approved Phase 4,Phase 2,Phase 3,Phase 1 99210-65-8, 215647-85-1
2
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
3
Ribavirin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 36791-04-5 37542
4
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 142217-69-4 153941
5
Atorvastatin Approved Phase 4 134523-00-5 60823
6
Sofosbuvir Approved Phase 4,Phase 2,Phase 3 1190307-88-0 45375808
7
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 154598-52-4 64139
8
Adefovir Dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
9
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 134678-17-4 60825
10
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
11
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
12
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
13
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
14
Pravastatin Approved Phase 4 81093-37-0 54687
15
Simeprevir Approved Phase 4 923604-59-5 66576988
16
Milk thistle Approved, Experimental, Investigational Phase 4,Phase 2,Phase 3 65666-07-1
17
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2 376348-65-1 3002977
18
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
19
Simvastatin Approved Phase 4 79902-63-9 54454
20
Zidovudine Approved Phase 4,Phase 3,Phase 2 30516-87-1 35370
21
Nevirapine Approved Phase 4,Phase 3,Phase 2 129618-40-2 4463
22
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2 54-85-3 3767
23
Pyrazinamide Approved, Investigational Phase 4,Phase 2,Phase 3 98-96-4 1046
24
Rifampicin Approved Phase 4,Phase 2,Phase 3 13292-46-1 5381226 5458213
25
Ethambutol Approved Phase 4,Phase 2,Phase 3 74-55-5 3279 14052
26
Emtricitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 143491-57-0 60877
27
Ledipasvir Approved Phase 4,Phase 2 1256388-51-8 67505836
28
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
29
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
30
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2 7440-70-2 271
31
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
32
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2 50-14-6 5280793
33
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 1406-16-2
34
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
35
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
37
Tenofovir Experimental, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 147127-20-6 464205
38
Adefovir Investigational Phase 4 106941-25-7
39
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
40
Cobalamin Experimental Phase 4 13408-78-1 6857388
41 interferons Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Antimetabolites Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Interferon alpha-2 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
50 Anticholesteremic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 395)
# Name Status NCT ID Phase Drugs
1 Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies Unknown status NCT00887081 Phase 4 PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin
2 Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment Unknown status NCT01724723 Phase 4 entecavir (BARACLUDE®)
3 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
4 Effects of Short-term Atorvastatin Treatment on Vaccination Efficacy in Nonresponder Persons to Hepatitis B Vaccine Unknown status NCT01548326 Phase 4 Atorvastatin;placebo
5 Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
6 Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B Completed NCT01639092 Phase 4 Tenofovir;Tenofovir;Entecavir
7 Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B Completed NCT01639066 Phase 4 Tenofovir;Entecavir;Tenofovir
8 A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B Completed NCT00380614 Phase 4 Lamivudine
9 Interferon α 2b Pharmacovigilance Study Completed NCT01841775 Phase 4 interferon α 2b + ribavirin
10 Liver Function After Intravenous Methylprednisolone Administration Completed NCT03667157 Phase 4 every week IVMP therapy;very high doses IVMP therapy
11 Evaluation of 2 Interferon γ Assays in the Diagnosis of Latent Tuberculosis in HIV-infected Patients.ANRS EP 40 QUANTI SPOT Completed NCT00647205 Phase 4
12 Rosuvastatin Versus Pravastatin in HIV Patients Treated With Boosted Protease Inhibitors (PI) (ANRS126) Completed NCT00117494 Phase 4 Pravastatin;Rosuvastatin
13 Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT) Completed NCT02624063 Phase 4 Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
14 Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. Completed NCT01195181 Phase 4 peginterferon plus ribavirin
15 Efficacy of Silymarin for Acute Hepatitis Completed NCT00412763 Phase 4 Silymarin (Silybum marianum)
16 A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B Completed NCT01327547 Phase 4 Maraviroc;Placebo
17 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
18 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
19 Long-Term Therapy With Ribavirin for Chronic Hepatitis C Completed NCT00001854 Phase 4 Ribavirin
20 Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery Completed NCT00656292 Phase 4 Simvastatin;Placebo
21 Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Recruiting NCT03854630 Phase 4 Engerix-B
22 HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure Recruiting NCT03642704 Phase 4 Reinforced preventive ARV therapy
23 Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission Recruiting NCT02937779 Phase 4 Tenofovir disoproxil fumarate
24 Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh. Active, not recruiting NCT02759991 Phase 4 Hecolin;Hepa-B
25 Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 Active, not recruiting NCT02057796 Phase 4 ART (Atripla, Truvada, Efavirenz, Combivir);Rifampin, isoniazid, pyrazinamide, ethambutol
26 Strategic Timing of Antiretroviral Treatment Active, not recruiting NCT00867048 Phase 4 All licensed antiretroviral medications
27 DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) Enrolling by invitation NCT03537196 Phase 4 Sofosbuvir 400 mg and Daclatasvir 60 mg;Sofosbuvir 400 mg and Daclatasvir 90 mg;Ribavirin;Sofosbuvir and Daclatasvir for 24 weeks
28 Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients Terminated NCT00122668 Phase 4 non-nucleoside reverse transcriptase inhibitors;nucleoside reverse transcriptase inhibitors;protease inhibitor
29 Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy Terminated NCT00122655 Phase 4 non-nucleoside reverse transcriptase inhibitors;nucleoside reverse transcriptase inhibitors;protease inhibitors
30 Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C Terminated NCT02120274 Phase 4 Vitamin D;Vitamin B 12
31 Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers Withdrawn NCT01766115 Phase 4 Telaprevir
32 Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients. Withdrawn NCT03279133 Phase 4 Ledipasvir 90mg/Sofosubvir 400mg
33 A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 Unknown status NCT02371408 Phase 2, Phase 3 ravidasvir hydrochloride;sofosbuvir;ribavirin
34 Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa Unknown status NCT01715922 Phase 2, Phase 3 Fluconazole;Flucytosine
35 A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B Unknown status NCT01172392 Phase 3 Pegylated interferon-alpha-2a;Nucleotidic or Nucleosidic Treatment
36 BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection Unknown status NCT01641016 Phase 2, Phase 3 efavirenz
37 Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C Completed NCT00265642 Phase 3 Irbesartan;placebo
38 Telbivudine Versus Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Completed NCT01595685 Phase 3 Telbivudine;Entecavir
39 Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis Completed NCT00116454 Phase 3 131 I-lipiodol
40 The Yellow Fever Vaccine Immunity in HIV Infected Patients : Development of New Assays for Virological and Immunological Monitoring in HIV Infected Patient. Completed NCT01426243 Phase 3
41 Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients Completed NCT00946595 Phase 2, Phase 3 efavirenz/emtricitabin/tenofovir;lopinavir/ritonavir
42 Initialization of Methadone in Primary Care, Randomized Intervention Research for Preventing HCV Transmission Practices Completed NCT00657397 Phase 3 Methadone
43 Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding Completed NCT00640263 Phase 3 lopinavir/ritonavir (LPV/r);Lamivudine (3TC)
44 Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA) Completed NCT00573001 Phase 3 Tenofovir/Emtricitabine (Truvada) and Nevirapine;Tenofovir/Emtricitabine/Efavirenz (Atripla);Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia);Tenofovir/Emtricitabine (Truvada) and Zidovudine
45 Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO) Completed NCT00495651 Phase 3 Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis;Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis
46 Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO) Completed NCT00495326 Phase 2, Phase 3 Nevirapine based therapy;Efavirenz based therapy;Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
47 Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load Completed NCT00454337 Phase 3 FTC/TDF + EFV or LPV/R +T20;FTC/TDF + EFV or LPV/R
48 Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136 Completed NCT00421551 Phase 3 Darunavir;ritonavir
49 Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients Completed NCT00391638 Phase 2, Phase 3 TRUVADA (EMTRICITABINE + TENOFOVIR DF)
50 Safety and Efficacy of Intradermal Injections of Newfill Versus Eutrophill in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132 SMILE Completed NCT00383734 Phase 3

Search NIH Clinical Center for Viral Hepatitis

Cochrane evidence based reviews: hepatitis, viral, animal

Sources

Genetic Tests for Viral Hepatitis

About this section
Sources

Anatomical Context for Viral Hepatitis

About this section

MalaCards organs/tissues related to Viral Hepatitis:

42
Testes, Liver, T Cells, Kidney, Bone, Monocytes, Brain
Sources

Publications for Viral Hepatitis

About this section

Articles related to Viral Hepatitis:

(show top 50) (show all 3236)
# Title Authors Year
1
Viral Hepatitis and Hepatocellular Carcinoma. ( 30593765 )
2019
2
Depletion of RIPK1 in hepatocytes exacerbates liver damage in fulminant viral hepatitis. ( 30622241 )
2019
3
High performance of intravoxel incoherent motion diffusion MRI in detecting viral hepatitis-b induced liver fibrosis. ( 30906743 )
2019
4
What Comes First: Treatment of Viral Hepatitis or Liver Cancer? ( 30874985 )
2019
5
Sero Conversion of Viral Hepatitis among End Stage Renal Disease Patients on Hemodialysis in Kashmir: Results of a Prospective Study. ( 30894917 )
2019
6
Screening, diagnosis and care cascade for viral hepatitis B and C in Yaoundé, Cameroon: a qualitative study of patients and health providers coping with uncertainty and unbearable costs. ( 30898817 )
2019
7
Circulating proteomic panels for diagnosis and risk stratification of acute-on-chronic liver failure in patients with viral hepatitis B. ( 30867825 )
2019
8
Viral Hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. ( 30817047 )
2019
9
Inflammasomes and their roles in the pathogenesis of viral hepatitis and their related complications; an updated systematic review. ( 30831142 )
2019
10
The study of regional peculiarities of parenteral viral hepatitis incidence dynamics among children as an instrument of developing complex regional social programs on the prevention of its increase. ( 30796870 )
2019
11
The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. ( 30800429 )
2019
12
Clinicoepidemiological characteristics of viral hepatitis in migrants and travellers of the +Redivi network. ( 30738196 )
2019
13
Evidence of sustained reductions in the relative risk of acute hepatitis B and C virus infections, and the increasing burden of hepatitis a virus infection in Egypt: comparison of sentinel acute viral hepatitis surveillance results, 2001-17. ( 30764780 )
2019
14
The impact of national viral hepatitis therapy program and hepatitis B vaccination program on mortality from acute and chronic viral hepatitis in Taiwan. ( 30706354 )
2019
15
A territory-wide prevalence study on blood-borne and enteric viral hepatitis in Hong Kong. ( 30668746 )
2019
16
Towards curative therapy of chronic viral hepatitis. ( 30641605 )
2019
17
Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. ( 30647010 )
2019
18
Elimination of viral hepatitis by 2030: ambitious, but achievable. ( 30647012 )
2019
19
Civil society's critical role in the elimination of viral hepatitis. ( 30647013 )
2019
20
Project ECHO: democratising knowledge for the elimination of viral hepatitis. ( 30647014 )
2019
21
Accelerating the elimination of viral hepatitis for Indigenous peoples. ( 30647015 )
2019
22
Awareness of Chronic Viral Hepatitis in the United States: An Update from National Health and Nutrition Examination Survey. ( 30629790 )
2019
23
Letter: the association between chronic viral hepatitis and metabolic syndrome. ( 30589966 )
2019
24
Letter: the association between chronic viral hepatitis and metabolic syndrome - Authors' reply. ( 30589967 )
2019
25
Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis. ( 30394948 )
2019
26
Need for recognizing atypical manifestations of childhood sporadic acute viral hepatitis warranting differences in management. ( 30269249 )
2019
27
Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum. ( 29354656 )
2018
28
Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. ( 29751763 )
2018
29
Tuberculosis and viral hepatitis infection in Eastern Europe, Asia, and Latin America: impact of tumor necrosis factor-I+ inhibitors in clinical practice. ( 29391775 )
2018
30
A Cross-Sectional Study of Viral Hepatitis Perception among Residents from Southeast and North Regions of Brazil. ( 29364166 )
2018
31
An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. ( 29757684 )
2018
32
Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). ( 29977962 )
2018
33
Impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma: a meta-analysis. ( 29947010 )
2018
34
Psychological Disorders and Quality of Life Among Patients With Chronic Viral Hepatitis: A Single-Center Cross-Sectional Study With Pair-Matched Healthy Controls. ( 29847395 )
2018
35
Opisthorchiasis and viral hepatitis b: clinical cases. ( 29602941 )
2018
36
Clinical epidemiology of chronic viral hepatitis B: A Tuscany real-word large-scale cohort study. ( 29844854 )
2018
37
Focus on histological abnormalities of intrahepatic vasculature in chronic viral hepatitis. ( 29427537 )
2018
38
Epidemiology, Genotype Distribution, Prognosis, Control, and Management of Viral Hepatitis B, C, D, and Hepatocellular Carcinoma in Mongolia. ( 29963464 )
2018
39
Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals? ( 29443655 )
2018
40
Unravelling the fate of functional PD1+ T cells in chronic viral hepatitis. ( 29309052 )
2018
41
Viral hepatitis: Biomarker for HBV therapy discontinuation. ( 29362470 )
2018
42
Lumbar synovial cyst with chronic viral hepatitis: A case series and literature review. ( 29724648 )
2018
43
Incorporation of Social Determinants of Health in the Peer-Reviewed Literature: A Systematic Review of Articles Authored by the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. ( 29874147 )
2018
44
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. ( 29406396 )
2018
45
Epidemiological, demographic and clinical data on chronic viral hepatitis C in Tuscany. ( 29847179 )
2018
46
Safety of biologic agents for psoriasis in patients with viral hepatitis. ( 29345515 )
2018
47
Anti-infective potential of catechins and their derivatives against viral hepatitis. ( 29399578 )
2018
48
High burden of hepatocellular carcinoma and viral hepatitis in Southern and Central Vietnam: Experience of a large tertiary referral center, 2010 to 2016. ( 29399285 )
2018
49
Psoriatic patients with chronic viral hepatitis do not have an increased risk of liver cirrhosis despite long-term methotrexate use: real-world data from a nationwide cohort study in Taiwan. ( 29753054 )
2018
50
Association of viral hepatitis and bipolar disorder: a nationwide population-based study. ( 29929549 )
2018
Sources

Variations for Viral Hepatitis

About this section
Sources

Expression for Viral Hepatitis

About this section
Search GEO for disease gene expression data for Viral Hepatitis.
Sources

Pathways for Viral Hepatitis

About this section

Pathways related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Toll-like Receptor Signaling Pathway 38 1
Show member pathways
 13.01 FAS FASLG IFNA1 IFNA2 TLR2 TNF
2
Human cytomegalovirus infection 38
Show member pathways
 12.81 FAS FASLG IFNA1 IFNA2 TLR2 TNF
3
PI3K-Akt signaling pathway 38
Show member pathways
 12.53 FAS FASLG IFNA1 IFNA2 MX1 TLR2
4
NF-kappaB Signaling 4
12.28 FAS FASLG IFNA1 TLR2 TNF
5
Selenium Micronutrient Network 1
Show member pathways
 12.18 ALB F2 GGT1 TNF
6
Proteoglycans in cancer 38
12.13 FAS FASLG TLR2 TNF
7
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.13 FAS FASLG IFNA1 IFNA2 TNF
8
Apoptosis and survival Caspase cascade 23
Show member pathways
 12.12 FAS FASLG KRT18 TNF
9
Tuberculosis 38
12.05 IFNA1 IFNA2 TLR2 TNF
10
Bacterial infections in CF airways 23
Show member pathways
 11.98 FAS FASLG TLR2 TNF
11
Influenza A 38
Show member pathways
 11.65 FAS FASLG IFNA1 IFNA2 MX1 TLR2
12
Necroptosis 38
Show member pathways
 11.59 FAS FASLG IFNA1 IFNA2 TNF
13
Photodynamic therapy-induced AP-1 survival signaling. 1
11.36 FAS FASLG TNF
14
FOXA2 and FOXA3 transcription factor networks 1
11.25 AFP ALB F2
15
Signal transduction_JNK pathway 23
11.22 FAS FASLG TNF
16
African trypanosomiasis 38
11.07 FAS FASLG TNF
17
Cori Cycle 1
10.77 G6PD GPT
Sources

GO Terms for Viral Hepatitis

About this section

Cellular components related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 AFP ALB F2 FAS FASLG FGL2
2 extracellular exosome GO:0070062 9.65 ALB F2 FAS FASLG FGL2 G6PD
3 endoplasmic reticulum lumen GO:0005788 9.62 AFP ALB F2 SERPINA1
4 membrane raft GO:0045121 9.56 FAS FASLG TLR2 TNF
5 extracellular space GO:0005615 9.36 AFP ALB F2 FASLG GGT1 GPT

Biological processes related to Viral Hepatitis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.91 FAS FASLG HFE TLR2 TNF
2 regulation of signaling receptor activity GO:0010469 9.85 F2 FASLG IFNA1 IFNA2 TNF
3 cytokine-mediated signaling pathway GO:0019221 9.84 FASLG IFNA1 IFNA2 TNF
4 cellular protein metabolic process GO:0044267 9.78 AFP ALB F2 SERPINA1
5 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.7 FAS FASLG TNF
6 tumor necrosis factor-mediated signaling pathway GO:0033209 9.67 FASLG KRT18 TNF
7 blood coagulation GO:0007596 9.67 F2 IFNA1 IFNA2 SERPINA1
8 type I interferon signaling pathway GO:0060337 9.61 IFNA1 IFNA2 MX1
9 apoptotic signaling pathway GO:0097190 9.58 FAS FASLG TNF
10 defense response GO:0006952 9.56 IFNA1 IFNA2 MX1 TNF
11 leukotriene metabolic process GO:0006691 9.55 GGT1 TLR2
12 humoral immune response GO:0006959 9.5 IFNA1 IFNA2 TNF
13 acute-phase response GO:0006953 9.33 F2 HFE SERPINA1
14 extrinsic apoptotic signaling pathway GO:0097191 9.26 FAS FASLG KRT18 TNF
15 necroptotic signaling pathway GO:0097527 8.8 FAS FASLG TNF

Molecular functions related to Viral Hepatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 FASLG IFNA1 IFNA2 TNF
2 identical protein binding GO:0042802 9.17 ALB FAS G6PD MX1 SERPINA1 TLR2
Sources

Sources for Viral Hepatitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....